On August 6, WUXI XDC rose 4.34% in regular trading, trading at 56.25 HKD/share, with turnover of 65.62 million HKD.

On the news front, the company is scheduled to hold a board meeting on August 24 to review its interim results for the first half of the year, with market expectations for the global ADC outsourcing leader's high-growth trajectory continuing to build. CLSA recently raised its target price to 82.6 HKD and maintained an \"outperform\" rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a \"buy\" rating and a 78 HKD target price, listing the company as a top pick in the China CXO sector.

Within the Life Sciences Tools & Services sector, peer stocks showed broad strength, with Genscript Bio up 4.91% and WuXi Bio up 2.46%. Global biotech financing recovery and robust ADC R&D investment are driving early positioning by institutional capital ahead of interim earnings disclosure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)